Your Story, Everywhere Investors Are Looking.

B2i Digital's media distribution network places your company's content across the financial publications and investor platforms that matter most.

When investors research a public company, they look in a dozen places before they ever visit its website. B2i Digital makes sure your story is already there, waiting for them. Through our media distribution network, we position your content across leading financial news sites, investor platforms, and content channels so your company shows up wherever the market is paying attention.

Our clients' content has appeared on platforms including these, among many others.

Recent premium placements include:

News, broadcast, and trade outlets carrying a single client announcement

0M+

Combined monthly audience across those outlets

0M+

Investors and market participants following our own channels

Where a client’s news lands

B2i in the middle. Six families of media and partners linking in.

Six families

Push and pull

Five families are where client news runs. The sixth is who links back to us: banks, conference partners and 35 public company client sites.

Financial and business media

14 of 16 sites shown

Investor data and trading platforms

9 of 16 platforms shown

Broadcast television and radio

12 of 53 stations shown

110+ network affiliate sites, coast to coast.

Regional news and daily press

6 of 16 papers shown

225+ USA TODAY Network newspaper sites.

Trade and industry press

8 of 14 publications shown

Banks, partners and client sites

11 of 46 shown

Plus Investing.com and 35 public company client sites.

800+

outlets reached by one announcement

330M+

combined monthly audience

1.7M+

social followers

The Power Is in the Combination

A single client announcement reaches more than 800 news, broadcast, and trade outlets with a combined audience of more than 330 million unique monthly visitors. No single tactic carries the day. It is the compounding effect of all of them, working in concert, that puts your company in front of investors again and again.

Media distribution

News and trade outlets

Social following

1.7M+ investors and participants

Nearly 70,000 opt-in investors

Paid advertising

Investor-targeted

Our own website

High authority, indexed

SMS

Client news reinforced by text, opt-in and growing

Within the micro and small cap arena we serve, B2i Digital ranks among the highest authority publishing platforms catering to public companies of our clients’ size.

The Matchmaking Funnel:
From Millions to One on One

Real capital gets committed in one on one conversations. Everything we do is built to carry your company down that path.

THE REACH

A company's biggest announcements can reach more than 800 news, broadcast, and trade outlets with a combined monthly audience of more than 330 million, reinforced across our social channels, email, SMS, and paid campaigns.

THE ROOM

At our investor conferences and events, hundreds of engaged investors see your company present directly.

THE MEETING

The one on one conversations with real investors that every public company is ultimately working toward. We can set them up because we know the room: a rolodex of 235,000+ capital markets contacts, by name.

This is what it means to be The Capital Markets Matchmaker℠. From Marketing to Meetings℠, we carry your story the full distance, from millions of impressions to the handful of conversations that change your company's trajectory.

Explore b2i Digital

B2i Digital partners with conferences like ROTH, Benchmark, Ladenburg Thalmann, OTC Markets, and the NYSE Growth Equity Symposium to connect the online and offline worlds.

Browse Conferences

Dig into each company's unique story, bios, and filed documents.

View Featured Companies

Industry experts vetted by B2i, providing hands-on support to active market companies.

Meet Our Experts

From Nasdaq to USA Today, see where client stories land and the audience behind them.

SEE THE MEDIA NETWORK

B2i Digital Spotlight

Featured Company

Lakewood-Amedex Biotherapeutics Inc. (Nasdaq: LABT)

Lakewood-Amedex Biotherapeutics Inc. is a clinical-stage biotechnology company developing the Bisphosphocin® class, a novel group of fast-acting, broad-spectrum antimicrobials, to treat infectious diseases and reduce the threat posed by antibiotic-resistant bacterial strains including MRSA and VRE.

View Company

Featured Conference

Growth Equity Symposium

The NYSE Growth Equity Symposium comes to 11 Wall Street on November 30, 2026. The event features NYSE-led educational programming and networking between investors and emerging growth issuers. The program concludes with a cocktail reception.

View Conference